Overview
- Lilly reported Tuesday at the European Congress on Obesity that patients who switched from Wegovy or Zepbound to its orforglipron pill kept most of their prior weight loss, maintaining about 79% and 75% respectively versus far less on placebo.
- In a separate Zepbound maintenance study, staying on the maximum tolerated dose held or slightly increased prior losses, while stepping down to 5 mg led to about 12 pounds of regain over a year.
- Novo Nordisk’s OASIS‑4 data showed the Wegovy pill delivered strong results, with early responders averaging 21.6% weight loss by week 64 and many participants reporting better mobility and daily function.
- New STEP UP analyses found higher‑dose semaglutide drove faster losses that were mostly from body fat, including large drops in visceral fat, with muscle strength largely preserved on testing.
- Foundayo is already FDA‑approved and on the U.S. market, and clinicians say oral GLP‑1 options could improve adherence by avoiding injections, cold storage, and clinic logistics while offering lower manufacturing costs.